{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:06Z","timestamp":1793159106406,"version":"4.5.0"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aberrant signaling through the fibroblast growth factor 19 (FGF19)\/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans. We have developed BLU9931, a potent and irreversible small-molecule inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway. BLU9931 is exquisitely selective for FGFR4 versus other FGFR family members and all other kinases. BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification. Approximately one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho \u03b2 (KLB) could potentially respond to treatment with an FGFR4 inhibitor. These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC.<\/jats:p>\n                  <jats:p>Significance: This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity. BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB. BLU9931 is the first FGFR4-selective molecule for the treatment of patients with HCC with aberrant FGFR4 signaling. Cancer Discov; 5(4); 424\u201337. \u00a92015 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Packer and Pollock, p. 355<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 333<\/jats:p>","DOI":"10.1158\/2159-8290.cd-14-1029","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T20:42:49Z","timestamp":1426538569000},"page":"424-437","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":296,"title":["First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway"],"prefix":"10.1158","volume":"5","author":[{"given":"Margit","family":"Hagel","sequence":"first","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Miduturu","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sheets","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nooreen","family":"Rubin","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifan","family":"Weng","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Stransky","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Bifulco","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kim","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hodous","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja","family":"Brooijmans","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Shutes","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Winter","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lengauer","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Kohl","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Guzi","sequence":"additional","affiliation":[{"name":"Blueprint Medicines, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2015,4,5]]},"reference":[{"key":"2022060700072627100_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrgastro.2014.10","article-title":"HCC therapies\u2014lessons learned","volume":"11","author":"W\u00f6rns","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022060700072627100_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2022060700072627100_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022060700072627100_bib4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.gastro.2011.12.039","article-title":"Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival","volume":"142","author":"Roessler","year":"2012","journal-title":"Gastroenterology"},{"key":"2022060700072627100_bib5","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"2022060700072627100_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"2022060700072627100_bib7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"2022060700072627100_bib8","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.27198","article-title":"Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification","volume":"60","author":"Ahn","year":"2014","journal-title":"Hepatology"},{"key":"2022060700072627100_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"2022060700072627100_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-4614-0887-1_12","article-title":"FGF19 and cancer","volume":"728","author":"Lin","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"2022060700072627100_bib11","doi-asserted-by":"crossref","first-page":"e17868","DOI":"10.1371\/journal.pone.0017868","article-title":"FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways","volume":"6","author":"Wu","year":"2011","journal-title":"PLoS One"},{"key":"2022060700072627100_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"},{"key":"2022060700072627100_bib13","doi-asserted-by":"crossref","first-page":"e36713","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PloS One"},{"key":"2022060700072627100_bib14","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2022060700072627100_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2022060700072627100_bib16","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"key":"2022060700072627100_bib17","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"key":"2022060700072627100_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov"},{"key":"2022060700072627100_bib19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem Biol"},{"key":"2022060700072627100_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2022060700072627100_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2010.02.007","article-title":"A structure-guided approach to creating covalent FGFR inhibitors","volume":"17","author":"Zhou","year":"2010","journal-title":"Chem Biol"},{"key":"2022060700072627100_bib22","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/jm0500931","article-title":"Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases","volume":"48","author":"Thompson","year":"2005","journal-title":"J Med Chem"},{"key":"2022060700072627100_bib23","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1093\/emboj\/17.20.5896","article-title":"Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain","volume":"17","author":"Mohammadi","year":"1998","journal-title":"EMBO J"},{"key":"2022060700072627100_bib24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2022060700072627100_bib25","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/onc.2009.432","article-title":"The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells","volume":"29","author":"Roidl","year":"2010","journal-title":"Oncogene"},{"key":"2022060700072627100_bib26","doi-asserted-by":"crossref","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci Transl Med"},{"key":"2022060700072627100_bib27","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"key":"2022060700072627100_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2022060700072627100_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nchembio.492","article-title":"Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine","volume":"7","author":"Hagel","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2022060700072627100_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2022060700072627100_bib31","doi-asserted-by":"crossref","first-page":"e85308","DOI":"10.1371\/journal.pone.0085308","article-title":"Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts","volume":"9","author":"Xin","year":"2014","journal-title":"PLoS One"},{"key":"2022060700072627100_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/toxsci\/kfs011","article-title":"Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys","volume":"126","author":"Pai","year":"2012","journal-title":"Toxicol Sci Off J Soc Toxicol"},{"key":"2022060700072627100_bib33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","article-title":"A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases","volume":"27","author":"Chen","year":"2007","journal-title":"Mol Cell"},{"key":"2022060700072627100_bib34","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2022060700072627100_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/5\/4\/424\/1822156\/424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/5\/4\/424\/1822156\/424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:07:54Z","timestamp":1654546074000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/5\/4\/424\/4943\/First-Selective-Small-Molecule-Inhibitor-of-FGFR4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,1]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,5]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-14-1029","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22530420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530417.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546177.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530420.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546177","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.725392673.793516798","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,1]]}}}